Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

INTRODUCTION: Upadacitinib (UPA) is an oral, selective Janus kinase inhibitor that has demonstrated favorable efficacy with an acceptable safety profile across a global, phase 3 program in rheumatoid arthritis (RA). This phase 2 open-label extension investigated the efficacy and safety of UPA throug...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivitz, Alan, Wells, Alvin F., Vargas, Juan I., Baraf, Herbert S. B., Rischmueller, Maureen, Klaff, Justin, Khan, Nasser, Li, Yihan, Carter, Kyle, Friedman, Alan, Durez, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193312/
https://www.ncbi.nlm.nih.gov/pubmed/37199884
http://dx.doi.org/10.1007/s40744-023-00557-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193312/
https://www.ncbi.nlm.nih.gov/pubmed/37199884
http://dx.doi.org/10.1007/s40744-023-00557-x

Ejemplares similares